Translational Control by Amino Acids and Energy

Handbook of Cell Signaling, Second Edition

Volumn 3, Issue , 2009, Pages 2285-2293

  Thedieck, Kathrin ^a   Hall, Michael N ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882884638     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374145-5.00274-6     Document Type: Chapter

References (110)

1. S Wullschleger, R Loewith and MN Hall (2006) TOR Signaling in growth and metabolism. Cell 124 471-484.
2. N Hay and N Sonenberg (2004) Upstream and downstream of mTOR. Genes Dev 18 1926-1945.
3. MN Corradetti and KL Guan (2006) Upstream of the mammalian target of rapamycin: do all roads pass through mTOR? Oncogene 25 6347-6360.
4. B Menand, T Desnos, L Nussaume, F Berger, D Bouchez, C Meyer and C Robaglia (2002) Expression and disruption of the Arabidopsis TOR (target of rapamycin) gene. Proc Natl Acad Sci USA 99 6422-6427.
5. X Long, C Spycher, ZS Han, AM Rose, F Muller and J Avruch (2002) TOR deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of mRNA translation. Curr Biol 12 1448-1461.
6. S Oldham, J Montagne, T Radimerski, G Thomas and E Hafen (2000) Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev 14 2689-2694.
7. H Zhang, JP Stallock, JC Ng, C Reinhard and TP Neufeld (2000) Regulation of cellular growth by the Drosophila target of rapamycin dTOR. Genes Dev 14 2712-2724.
8. EJ Brown, MW Albers, TB Shin, K Ichikawa, CT Keith, WS Lane and SL Schreiber (1994) A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 369 756-758.
9. MI Chiu, H Katz and V Berlin (1994) RAPT1, a mammalian homolog of yeast Tor, interacts with the FKBP12/rapamycin complex. Proc Natl Acad Sci USA 91 12,574-12,578.
10. DM Sabatini, H Erdjument-Bromage, M Lui, P Tempst and SH Snyder (1994) RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78 35-43.
11. J Kunz, R Henriquez, U Schneider, M Deuter-Reinhard, NR Movva and MN Hall (1993) Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell 73 585-596.
12. YG Gangloff, M Mueller, SG Dann, P Svoboda, M Sticker, JF Spetz, SH Um, EJ Brown, S Cereghini, G Thomas and SC Kozma (2004) Disruption of the mouse mTOR gene leads to early postimplantation lethality and prohibits embryonic stem cell development. Mol Cell Biol 24 9508-9516.
13. R Loewith, E Jacinto, S Wullschleger, A Lorberg, JL Crespo, D Bonenfant, W Oppliger, P Jenoe and MN Hall (2002) Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10 457-468.
14. E Jacinto, R Loewith, A Schmidt, S Lin, MA Ruegg, A Hall and MN Hall (2004) Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 6 1122-1128.
15. DD Sarbassov, SM Ali, DH Kim, DA Guertin, RR Latek, H Erdjument-Bromage, P Tempst and DM Sabatini (2004) Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 1296-1302.
16. DH Kim, DD Sarbassov, SM Ali, JE King, RR Latek, H Erdjument-Bromage, P Tempst and DM Sabatini (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110 163-175.
17. K Hara, Y Maruki, X Long, K Yoshino, N Oshiro, S Hidayat, C Tokunaga, J Avruch and K Yonezawa (2002) Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 177-189.
18. Y Sancak, CC Thoreen, TR Peterson, RA Lindquist, SA Kang, E Spooner, SA Carr and DM Sabatini (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25 903-915.
19. E Vander Haar, SI Lee, S Bandhakavi, TJ Griffin and DH Kim (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9 316-323.
20. L Wang, TE Harris, RA Roth and JC Lawrence Jr. (2007) PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 282 20,036-20,044.
21. N Oshiro, R Takahashi, K Yoshino, K Tanimura, A Nakashima, S Eguchi, T Miyamoto, K Hara, K Takehana, J Avruch, U Kikkawa and K Yonezawa (2007) The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1. J Biol Chem 282 20,329-20,339.
22. BD Fonseca, EM Smith, VH Lee, C Mackintosh and CG Proud (2007) PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 282 24,514-24,524.
23. K Thedieck, P Polak, ML Kim, KD Molle, A Cohen, P Jeno, C Arrieumerlou and MN Hall (2007) PRAS40 and PRR5-Like protein are new mTOR interactors that regulate apoptosis. PLoS. ONE 2 e1217.
24. MA Frias, CC Thoreen, JD Jaffe, W Schroder, T Sculley, SA Carr and DM Sabatini (2006) mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 16 1865-1870.
25. Q Yang, K Inoki, T Ikenoue and KL Guan (2006) Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev 20 2820-2832.
26. E Jacinto, V Facchinetti, D Liu, N Soto, S Wei, SY Jung, Q Huang, J Qin and B Su (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127 125-137.
27. LR Pearce, X Huang, J Boudeau, R Pawlowski, S Wullschleger, M Deak, AF Ibrahim, R Gourlay, MA Magnuson and DR Alessi (2007) Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem J 405 513-522.
28. SY Woo, DH Kim, CB Jun, YM Kim, EV Haar, SI Lee, JW Hegg, S Bandhakavi, TJ Griffin and DH Kim (2007) PRR5, a novel component of mTOR complex 2, regulates platelet-derived growth factor receptor beta expression and signaling. J Biol Chem 282 25,604-25,612.
29. C Shiota, JT Woo, J Lindner, KD Shelton and MA Magnuson (2006) Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell 11 583-589.
30. DA Guertin, DM Stevens, CC Thoreen, AA Burds, NY Kalaany, J Moffat, M Brown, KJ Fitzgerald and DM Sabatini (2006) Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell 11 859-871.
31. DJ Kwiatkowski (2003) Tuberous sclerosis: from tubers to mTOR. Ann Hum Genet 67 87-96.
32. PB Crino, KL Nathanson and EP Henske (2006) The tuberous sclerosis complex. N Engl J Med 355 1345-1356.
33. Y Zhang, X Gao, LJ Saucedo, B Ru, BA Edgar and D Pan (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5 578-581.
34. A Garami, FJ Zwartkruis, T Nobukuni, M Joaquin, M Roccio, H Stocker, SC Kozma, E Hafen, JL Bos and G Thomas (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11 1457-1466.
35. J Avruch, K Hara, Y Lin, M Liu, X Long, S Ortiz-Vega and K Yonezawa (2006) Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase. Oncogene 25 6361-6372.
36. X Long, Y Lin, S Ortiz-Vega, K Yonezawa and J Avruch (2005) Rheb binds and regulates the mTOR kinase. Curr Biol 15 702-713.
37. PB Dennis, A Jaeschke, M Saitoh, B Fowler, SC Kozma and G Thomas (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294 1102-1105.
38. K Inoki, T Zhu and KL Guan (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 577-590.
39. RJ Shaw and LC Cantley (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441 424-430.
40. T Nobukuni, M Joaquin, M Roccio, SG Dann, SY Kim, P Gulati, MP Byfield, JM Backer, F Natt, JL Bos, FJ Zwartkruis and G Thomas (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102 14,238-14,243.
41. PE Burnett, RK Barrow, NA Cohen, SH Snyder and DM Sabatini (1998) RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA 95 1432-1437.
42. GJ Brunn, P Fadden, TA Haystead and JC Lawrence Jr. (1997) The mammalian target of rapamycin phosphorylates sites having a (Ser/Thr)-Pro motif and is activated by antibodies to a region near its COOH terminus. J Biol Chem 272 32,547-32,550.
43. H Nojima, C Tokunaga, S Eguchi, N Oshiro, S Hidayat, K Yoshino, K Hara, N Tanaka, J Avruch and K Yonezawa (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278 15,461-15,464.
44. KM Choi, LP McMahon and JC. Lawrence Jr. (2003) Two motifs in the translational repressor PHAS-I required for efficient phosphorylation by mammalian target of rapamycin and for recognition by raptor. J Biol Chem 278 19,667-19,673.
45. A Beugnet, X Wang and CG Proud (2003) Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TOR-dependent phosphorylation of initiation factor 4E-binding protein 1. J Biol Chem 278 40,717-40,722.
46. RB Pearson, PB Dennis, JW Han, NA Williamson, SC Kozma, RE Wettenhall and G Thomas (1995) The principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domain. EMBO J 14 5279-5287.
47. E Jacinto and A Lorberg (2008) TOR regulation of AGC kinases in yeast and mammals. Biochem. J. 410 19-37.
48. AC Gingras, SP Gygi, B Raught, RD Polakiewicz, RT Abraham, MF Hoekstra, R Aebersold and N Sonenberg (1999) Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 13 1422-1437.
49. I Mothe-Satney, GJ Brunn, LP McMahon, CT Capaldo, RT Abraham and JC. Lawrence Jr. (2000) Mammalian target of rapamycin-dependent phosphorylation of PHAS-I in four (S/T)P sites detected by phospho-specific antibodies. J Biol Chem 275 33,836-33,843.
50. AC Gingras, B Raught, SP Gygi, A Niedzwiecka, M Miron, SK Burley, RD Polakiewicz, A Wyslouch-Cieszynska, R Aebersold and N Sonenberg (2001) Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15 2852-2864.
51. X Wang, A Beugnet, M Murakami, S Yamanaka and CG Proud (2005) Distinct signaling events downstream of mTOR cooperate to mediate the effects of amino acids and insulin on initiation factor 4E-binding proteins. Mol Cell Biol 25 2558-2572.
52. X Wang, W Li, JL Parra, A Beugnet and CG Proud (2003) The C terminus of initiation factor 4E-binding protein 1 contains multiple regulatory features that influence its function and phosphorylation. Mol Cell Biol 23 1546-1557.
53. D Yang, GJ Brunn and JC. Lawrence Jr. (1999) Mutational analysis of sites in the translational regulator, PHAS-I, that are selectively phosphorylated by mTOR. FEBS Lett 453 387-390.
54. K Hara, K Yonezawa, QP Weng, MT Kozlowski, C Belham and J Avruch (1998) Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 273 14,484-14,494.
55. CG Proud (2007) Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem J 403 217-234.
56. B Raught, F Peiretti, AC Gingras, M Livingstone, D Shahbazian, GL Mayeur, RD Polakiewicz, N Sonenberg and JW Hershey (2004) Phosphorylation of eucaryotic translation initiation factor 4B Ser422 is modulated by S6 kinases. EMBO J 23 1761-1769.
57. MK Holz, BA Ballif, SP Gygi and J Blenis (2005) mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. Cell 123 569-580.
58. D Shahbazian, PP Roux, V Mieulet, MS Cohen, B Raught, J Taunton, JW Hershey, J Blenis, M Pende and N Sonenberg (2006) The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 25 2781-2791.
59. NV Dorrello, A Peschiaroli, D Guardavaccaro, NH Colburn, NE Sherman and M Pagano (2006) S6K1- and βTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth. Science 314 467-471.
60. I Ruvinsky, N Sharon, T Lerer, H Cohen, M Stolovich-Rain, T Nir, Y Dor, P Zisman and O Meyuhas (2005) Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev 19 2199-2211.
61. X Wang, W Li, M Williams, N Terada, DR Alessi and CG Proud (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20 4370-4379.
62. KM Hannan, Y Brandenburger, A Jenkins, K Sharkey, A Cavanaugh, L Rothblum, T Moss, G Poortinga, GA McArthur, RB Pearson and RD Hannan (2003) mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol Cell Biol 23 8862-8877.
63. C Mayer, J Zhao, X Yuan and I Grummt (2004) mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev 18 423-434.
64. JR McMullen, T Shioi, L Zhang, O Tarnavski, MC Sherwood, AL Dorfman, S Longnus, M Pende, KA Martin, J Blenis, G Thomas and S Izumo (2004) Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol Cell Biol 24 6231-6240.
65. I Ruvinsky and O Meyuhas (2006) Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem Sci 31 342-348.
66. E Hornstein, H Tang and O Meyuhas (2001) Mitogenic and nutritional signals are transduced into translational efficiency of TOP mRNAs. Cold Spring Harb Symp Quant Biol 66 477-484.
67. HB Jefferies, C Reinhard, SC Kozma and G Thomas (1994) Rapamycin selectively represses translation of the “polypyrimidine tract” mRNA family. Proc Natl Acad Sci USA 91 4441-4445.
68. H Tang, E Hornstein, M Stolovich, G Levy, M Livingstone, D Templeton, J Avruch and O Meyuhas (2001) Amino acid-induced translation of TOP mRNAs is fully dependent on phosphatidylinositol 3-kinase-mediated signaling, is partially inhibited by rapamycin, and is independent of S6K1 and rpS6 phosphorylation. Mol Cell Biol 21 8671-8683.
69. M Stolovich, H Tang, E Hornstein, G Levy, R Cohen, SS Bae, MJ Birnbaum and O Meyuhas (2002) Transduction of growth or mitogenic signals into translational activation of TOP mRNAs is fully reliant on the phosphatidylinositol 3-kinase-mediated pathway but requires neither S6K1 nor rpS6 phosphorylation. Mol Cell Biol 22 8101-8113.
70. D Barth-Baus, CA Stratton, L Parrott, H Myerson, O Meyuhas, DJ Templeton, GE Landreth and JO Hensold (2002) S6 phosphorylation-independent pathways regulate translation of 5'-terminal oligopyrimidine tract-containing mRNAs in differentiating hematopoietic cells. Nucleic Acids Res 30 1919-1928.
71. M Stolovich, T Lerer, Y Bolkier, H Cohen and O Meyuhas (2005) Lithium can relieve translational repression of TOP mRNAs elicited by various blocks along the cell cycle in a glycogen synthase kinase-3- and S6-kinase-independent manner. J Biol Chem 280 5336-5342.
72. M Pende, SH Um, V Mieulet, M Sticker, VL Goss, J Mestan, M Mueller, S Fumagalli, SC Kozma and G Thomas (2004) S6K1(−/−)/S6K2(−/−) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24 3112-3124.
73. H Shima, M Pende, Y Chen, S Fumagalli, G Thomas and SC Kozma (1998) Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J 17 6649-6659.
74. PB Dennis, A Jaeschke, M Saitoh, B Fowler, SC Kozma and G Thomas (2001) Mammalian TOR: a homeostatic ATP sensor. Science 294 1102-1105.
75. D Carling (2004) The AMP-activated protein kinase cascade: a unifying system for energy control. Trends Biochem Sci 29 18-24.
76. MN Corradetti, K Inoki, N Bardeesy, RA DePinho and KL Guan (2004) Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18 1533-1538.
77. RJ Shaw, N Bardeesy, BD Manning, L Lopez, M Kosmatka, RA DePinho and LC Cantley (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6 91-99.
78. DM Gwinn, DB Shackelford, DF Egan, MM Mihaylova, A Mery, DS Vasquez, BE Turk and RJ Shaw (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30 214-226.
79. SA Hawley, J Boudeau, JL Reid, KJ Mustard, L Udd, TP Makela, DR Alessi and DG Hardie (2003) Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2 28.
80. RJ Shaw, M Kosmatka, N Bardeesy, RL Hurley, LA Witters, RA DePinho and LC Cantley (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101 3329-3335.
81. A Woods, SR Johnstone, K Dickerson, FC Leiper, LG Fryer, D Neumann, U Schlattner, T Wallimann, M Carlson and D Carling (2003) LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13 2004-2008.
82. A Hemminki, D Markie, I Tomlinson, E Avizienyte, S Roth, A Loukola, G Bignell, W Warren, M Aminoff, P Hoglund, H Jarvinen, P Kristo, K Pelin, M Ridanpaa, R Salovaara, T Toro, W Bodmer, S Olschwang, AS Olsen, MR Stratton, CA de la and LA Aaltonen (1998) A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391 184-187.
83. DE Jenne, H Reimann, J Nezu, W Friedel, S Loff, R Jeschke, O Muller, W Back and M Zimmer (1998) Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 18 38-43.
84. RJ Shaw, KA Lamia, D Vasquez, SH Koo, N Bardeesy, RA DePinho, M Montminy and LC Cantley (2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 1642-1646.
85. JM Lizcano, O Goransson, R Toth, M Deak, NA Morrice, J Boudeau, SA Hawley, L Udd, TP Makela, DG Hardie and DR Alessi (2004) LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J 23 833-843.
86. RJ Dowling, M Zakikhani, IG Fantus, M Pollak and N Sonenberg (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67 10,804-10,812.
87. G Zhou, R Myers, Y Li, Y Chen, X Shen, J Fenyk-Melody, M Wu, J Ventre, T Doebber, N Fujii, N Musi, MF Hirshman, LJ Goodyear and DE Moller (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108 1167-1174.
88. N Musi, MF Hirshman, J Nygren, M Svanfeldt, P Bavenholm, O Rooyackers, G Zhou, JM Williamson, O Ljunqvist, S Efendic, DE Moller, A Thorell and LJ Goodyear (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 2074-2081.
89. A Vlad, S Rohrs, L Klein-Hitpass and O Muller (2007) The first five years of the Wnt targetome. Cell Signal 20 795-802.
90. K Inoki, H Ouyang, T Zhu, C Lindvall, Y Wang, X Zhang, Q Yang, C Bennett, Y Harada, K Stankunas, CY Wang, X He, OA MacDougald, M You, BO Williams and KL Guan (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126 955-968.
91. GJ Browne, SG Finn and CG Proud (2004) Stimulation of the AMP-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem 279 12,220-12,231.
92. S Horman, C Beauloye, D Vertommen, JL Vanoverschelde, L Hue and MH Rider (2003) Myocardial ischemia and increased heart work modulatethe phosphorylation state of eukaryotic elongation factor-2. J Biol Chem 278 41,970-41,976.
93. DM Thomson, CA Fick and SE Gordon (2008) AMPK Activation Attenuates S6K1, 4E-BP1, and eEF2 Signaling Responses to High-frequency Electrically Stimulated Skeletal Muscle Contractions. J Appl Physiol 104 625-632.
94. EM Smith, SG Finn, AR Tee, GJ Browne and CG Proud (2005) The tuberous sclerosis protein TSC2 is not required for the regulation of the mammalian target of rapamycin by amino acids and certain cellular stresses. J Biol Chem 280 18,717-18,727.
95. LW Ellisen (2005) Growth control under stress: mTOR regulation through the REDD1-TSC pathway. Cell Cycle 4 1500-1502.
96. MP DeYoung, P Horak, A Sofer, D Sgroi and LW Ellisen (2008) Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22 239-251.
97. SR Kimball, AN Do, L Kutzler, DR Cavener and LS Jefferson (2008) Rapid Turnover of the mTOR Complex 1 (mTORC1) Repressor REDD1 and Activation of mTORC1 Signaling following Inhibition of Protein Synthesis. J Biol Chem 283 3465-3475.
98. A Beugnet, AR Tee, PM Taylor and CG Proud (2003) Regulation of targets of mTOR (mammalian target of rapamycin) signalling by intracellular amino acid availability. Biochem J 372 555-566.
99. M Roccio, JL Bos and FJ Zwartkruis (2006) Regulation of the small GTPase Rheb by amino acids. Oncogene 25 657-664.
100. X Long, S Ortiz-Vega, Y Lin and J Avruch (2005) Rheb binding to mammalian target of rapamycin (mTOR) is regulated by amino acid sufficiency. J Biol Chem 280 23,433-23,436.
101. YC Hsu, JJ Chern, Y Cai, M Liu and KW Choi (2007) Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445 785-788.
102. X Bai, D Ma, A Liu, X Shen, QJ Wang, Y Liu and Y Jiang (2007) Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318 977-980.
103. Y Sancak, TR Peterson, YD Shaul, RA Lindquist, CC Thoreen, L Bar-Peled and DM Sabatini (2008) The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320 1496-1501.
104. E Kim, P Goraksha-Hicks, L Li, TP Neufeld and KL Guan (2008) Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10 935-945.
105. T Nobukuni, M Joaquin, M Roccio, SG Dann, SY Kim, P Gulati, MP Byfield, JM Backer, F Natt, JL Bos, FJ Zwartkruis and G Thomas (2005) Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc Natl Acad Sci USA 102 14,238-14,243.
106. MP Byfield, JT Murray and JM Backer (2005) hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280 33,076-33,082.
107. GM Findlay, L Yan, J Procter, V Mieulet and RF Lamb (2007) A MAP4 kinase related to Ste20 is a nutrient-sensitive regulator of mTOR signalling. Biochem J 403 13-20.
108. X Wang and CG Proud (2007) A novel mechanism for the control of translation initiation by amino acids, mediated by phosphorylation of eukaryotic initiation factor eIF2B. Mol Cell Biol 28 1429-1442.
109. D Cota, K Proulx, KA Smith, SC Kozma, G Thomas, SC Woods and RJ Seeley (2006) Hypothalamic mTOR signaling regulates food intake. Science 312 927-930.
110. Y Minokoshi, T Alquier, N Furukawa, YB Kim, A Lee, B Xue, J Mu, F Foufelle, P Ferre, MJ Birnbaum, BJ Stuck and BB Kahn (2004) AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428 569-574.